



Publication: Business Today (print) Date : August 14, 2016 Page : 1 of 1

: Biotech Battles

Title

PHARMA Biotech BIOTECH BATTLES

INDIAN DRUG MAKERS ARE SLUGGING IT OUT WITH BIG PHARMA OVER LAUNCH OF BIOSIMILARS. WILL THEY BE ABLE TO HOLD THEIR FORT IN THIS EMERGING SPACE?

BY E. KUMAR SHARMA

n June 27. Hyderabad-based Hetero Drugs, big producer of HIV/AIDS drugs, ananced the launch of a biosimilar, evacizumab, for treatment of colorectal ncer. The drug is estimated to have a potential market of close to ₹180 crore. But there is a hitch. Roche, the company that had discovered the drug has challenged the approval to the biosimilar in the Delhi High Court. The drug is being sold on the basis of the regulatory approval.

Roche's action was expected. Other drug companies - whether it is Biocon, Mylan, Reliance Life Sciences and, now. Hetero — have, for over two years now, been battling legal challenges to their biosimilars from innovator companies such as Roche. Anticipating such an action, Ahmedabad-based Zydus Cadila approached the Mumbai High Court a few months ago for restraining the innovator

company from challenging the biosimilar of its breast cancer drug Trastuzumab that it had launched in January

This, say market watchers, is just a start. Given that at stake are drugs with markets worth billions of dollars, the battle between global pharmaceutical giants and Indian biosimilar makers is unlikely to abate. The fight will, if anything, intensify, as more and more Indian companies try to tap the opportunities in the biosimilar space, which some see as the next growth frontier given the limited opportunities in the increasingly competitive generics market. Also, many of the newer drugs, especially for cancer care, are biotech drugs.

A biosimilar is a drug with properties that are similar to another that has been licensed previously. Biosimilars, like generics, are a competition to innovator drugs. A generic drug is a chemically derived medicinal product made

70 BUSINESS TODAY August 14 2016



# **PHARMA** Biotech

of pure chemical substances whose structure can be easily identified whereas a biosimilar is a medicinal product of biological origin with a structure that is more complex

than that of a generic drug. Pratibha Singh, an intellectual property, or IP, lawyer and a member of the IPR Think Tank that drafted the National IPR (intellectual property rights) policy, says, "Biosimilars are the next big thing. The Indian industry poses a huge threat to the innovator companies, just like it did in generics." Aware that the competition in small molecules has limited the scope for growth in generics, almost all top 20 Indian pharmaceutical companies are entering the space. Some are going abroad, too. For Japan. In February last year, Ahmedabad-based Intas Pharmaceuticals had launched a biosimilar in EU, the US and Japan markets. "The period between 2015 and 2020 will see many products go off patent," says Bitika Sharma, Partner, Singh & Singh Lall & Sethi, a leading IP law firm (co-founded by Pratibha Singh and others).

This will be a huge opportunity for Indian companies - while biosimilars are costlier to make, they are also several times more expensive than generics — provided they can manage the maze of complex regulations and judicial challenges.

Off-Patent

In all the court cases, the multinational company, or MNC, is Roche. This has partly to do with the fact that the Swiss healthcare giant has arguably the biggest portfolio of cancer drugs in critical areas. Its strategy, say people in the biosimilars camp, involves taking companies to court even if the original drug has gone off patent. It questions the drug on the grounds of it being called a biosimilar and a copy of its product (implying that the Indian company is trying to benefit from the reputation it has earned on its drug).

Arguments around these lines, say some, have created a cloud over the way the approvals are granted. "The court wanted to peruse whether these companies were complying with the 2012 biosimilar guidelines or not, and whether there are sufficient safeguards in the Drugs & Cosmetics Act that are in consonance with the guidelines or not. These matters are pending," says Sharma. The courts, she says, "are also looking into the extent to which these suits by innovator companies are maintainable". In other words, the question is, what rights they enjoy over a drug when there is no patent or trademark violation and there is no issue of data exclusivity (as it is not recognised in India).

Rising Tide/Evolving Guidelines While India's biosimilar market is still small, the stakes are

#### HOW THEY STACK UP The leading biotech products and their biosimilar makers

PRODUCT	MARKET SIZE (₹ CRORE) 1,400	INNOVATOR BRAND Huminsulin	INNOVATOR COMPANY Lilly	BIOPHARMA/BIOSIMILAR MAKERS Novo Nordisk, Biocon, Lupin, Aventis
RITUXIMAB	200	Ristova	Roche	DRL, Reliance Life Sciences, Intas, Emcure, Lupin, Hetero
BEVACIZUMAB	180	Avastin	Roche	Reliance Life Sciences, Hetero
ERYTHROPOIETIN	130	Eprex	J&J	Zydus, Reliance Life Sciences, Emcure, Wockhardt, Biocon, Intas
FSH*	52	Gonal-F	Merck Serono	Bharat Serum, MSD, Reliance Life Sciences, Intas, Sun, Corona, LG, Emcure
PEG-GSCF	45	Neulasta	Roche	DRL, Intas, Abbott, Emcure, Zydus
RETEPLASE	30	Retavase	Boehringer Ingelheim	Reliance Life Sciences
INTERFERON BETA	30	Avonex	Biogen Idec/UCB	Reliance Life Sciences
ADALIMUMAB	20	HUMIRA	ABBVIE	Zydus, Reliance Life Sciences, Torren

\* Follicle Stimulating Hormone Source: Industry

72 BUSINESS TODAY August 14 2016

getting bigger as it attracts more and more players. Industry estimates suggest that the potential market for biosimilars in India is over ₹2,500 crore. Just Roche's Trastuzumab and Bevacizumab have a ₹600-crore market, according to estimates. The total pharmaceutical market

is worth ₹1 lakh crore. The regulations, however, have not kept pace with the changing market. One reason for court battles is the scope for different interpre tations. Biosimilar makers say the is-SLUGGING IT OUT sues will be sorted out soon. "Wherever The biosimilar battles already there is a scope for different interpretabeing fought in Indian courts tions, it will get addressed with strengthening of regulatory systems Swiss healthcare major Roche and new guidelines," says Biocon has challenged the launch of two major cancer drugs in India -Trastuzumab and Bevacizumab

G.N. Singh, the Drug Controller General of India (DCGI), while opting not to comment on its approvals being challenged, says, "The new biosimilar guidelines, which will be out in about three weeks, are going to change the approval process. They will address all the issues and make India a favourable destination for these drugs." He is confident of addressing the concerns of MNCs, too. "It took us one and a half years to prepare the guidelines. We have taken inputs from stakeholders,

Chairperson & MD Kiran Mazumdar-

including MNCs." But that may not be the end of all the problems as there is a view that biosimilars, by their very nature, are prone to litigation. "The patent landscape in biologics is much more complex than



The innovator company in both

cases, Roche, has objected to the

drugs being called biosimilar variants of its products

Biocon, Mylan, Reliance Life Sciences and Hetero Drugs have

launched these biosimilars in India

The two drugs have a market of

according to industry estimates

They have been launched after approvals from the drug controller

The outcome of the court battle

similar makers and innovators

could have implications for other

FOR DIFFERENT INTERPRETATIONS. IT WILL GET ADDRESSED WITH STRENGTHENING OF REGULATORY SYSTEMS AND NEW GUIDELINES' KIRAN MAZUMDAR-SHAW/ CHAIRPERSON & MD. BIOCON

"WHEREVER THERE IS A SCOPE

in small molecules, leaving a lot of scope for litigation and opposition," says G.V. Prasad, Co-chairman and CEO, Dr. Reddy's. He says in biologics, there are various patents. such as for the clone, the process, and others. "A small about 100 patents. There is a lot of complexity. That is one part. The other is the structure. A small molecule is easier to characterise and design than a large molecule. So, establishing one-to-one equivalence is challenging." That is why the product's sameness can be questioned. "It is like saying that two human beings are similar but not identical - both have two legs, two hands, two eyes and one head, but are not the same. This is not the case with small molecules, whose exact equivalence can be proved. These two things make it tough to get approvals and leave a lot of scope for litigation and opposition."

Basis of Questioning

Some within the industry say these cases are setting a bad precedent. "Generally speaking, any regulatory approval should not be questioned in a court. It is unfortunate that this is happening in India," says Mazumdar-Shaw. But others say this happens even in the US.

"As long as the biosimilar has the approval of the committee of subject experts and the DCGI and there are no patent or data protection issues, it should not be a problem," says a senior executive of an Indian pharmaceutical company who did not want to be identified. This argument is in sync with the line many biosimilar companies are taking. Some, pointing to the Reliance and Roche case over Trastuzumab, say the latter should have appealed to the DCGI

> Roche has its own arguments. "We have taken this action because as the holder of the Herceptin trademark and the innovator of Trastuzumab, we have a duty to ensure that if a company claims its

August 14 2016 BUSINESS TODAY 73

## PHARMA Biotech

"THE PATENT LANDSCAPE IN **BIOLOGICS IS MUCH MORE** COMPLEX THAN IN SMALL MOLECULES, LEAVING A LOT OF SCOPE FOR LITIGATION AND OPPOSITION" G.V. PRASAD/ Co-Chairman & CEO/ Dr. Reddy's



product is a biosimilar of, or similar to our innovator product Trastuzumab, then it satisfies the criteria for a biosimilar," says its website.

## Pricing Challenges

Rough calculations suggest that a biosimilar brings down the price of a drug by 30-60 per cent. In generics, the fall is much steeper. For example, when a drug is launched after approval under the Abbreviated New Drug Application, or ANDA, the price reduction can be as high as 95 per cent. This is due to the different cost structures. If, for instance, launching a generic drug under the ANDA costs a couple of million dollars, a biosimilar launch would

That is one reason why the big MNCs are also looking at biosimilars. "The innovator companies are also becoming aggressive in biosimilars, Amgen directly and Biogen through its joint venture with Samsung," says Subir Basak, a management consultant who has spent years working at both innovator companies such as Amgen and Merck in the US as well as companies that make biosimilars such as Intas and Dr. Reddy's. Novartis's Sandoz is already a known name in this space. Although it is early days to talk  $\,$   $\,$  the list does not get any longer.  $\blacklozenge$ about price cuts and benefits such as higher market share, typically, the reduction in the price of the original drug

after the launch of the biosimilar is in the range of 10-20 per cent. However, no innovator has launched a biosimilar in India yet. "The probability of an innovator-developed biosimilar being launched in India is low. But there is always a possibility of an authorised biosimilar product being made available in India," says Chandru Chawla, who heads corporate strategy at Cipla and also heads Cipla New Ventures, which includes Cipla BioTec, a company focused on "affordable and accessible biopharmaceuticals".

#### Missing Drugs

There is one worrying dimension that needs to be looked at. Some cancer specialists have been raising the issue of non-availability of latest cancer drugs in India. Oncologist Radheshyam Naik, who treats about 300 patients every month at HealthCare Global Enterprises, a Bangalorebased chain that specialises in caring for cancer patients, says, "At least a third of my patients need some of these latest drugs so that cancer control can be more effective. Whether they can afford it or not, the fact of the matter is that there are drugs available outside India that my patients need but do not get." One of his concerns is whether this has got to do with the rise of biosimilars in India.

Those within the industry, however, say the absence of a global product from India does not prevent an Indian company from launching a biosimilar here. A good case in point is Zydus Cadila, which in December 2014 launched Exemptia, the world's first biosimilar of Adalimumab through what it called "a non-infringing process and noninfringing formulation". The drug is used to treat rheumatoid arthritis and other auto-immune disorders (the innovator drug is AbbVie's Humira). Pankaj R. Patel, Chairman and Managing Director of Zydus Cadila, says, "We made a therapy that was until then unavailable to Indian patients suffering from inflammatory arthritis. Biosimilars address the twin aspects of access and affordability."

The perceived reluctance to launch new drugs is driven by commercial and strategic reasons as most of these are high-priced and, therefore, have a tiny market. Also, if the MNCs were to lower the price for India, it could have an impact in their home markets, as consumers, insurance companies and regulators in some countries like the US are increasingly demanding better value for what is being spent on patients. In the US, high-priced drugs have even become an election issue. There have been media reports of Hillary Clinton's attacks on Valeant Pharmaceuticals over what she called "predatory pricing". Clinton is the Democratic nominee for the presidential race.

Whatever the reason, the dilemma of a doctor or patient who knows a drug exists but is not available is real. "Some 15 to 16 new drugs over the last three years or so have not been launched in India," says Dr. Naik. Let's hope

@EKumarSharma

74 BUSINESS TODAY August 14 2016